Improving medicines with transdermal technology
Starton is a clinical-stage biotechnology company focused on transforming standard of care therapeutics. Starton uses proven transdermal technology with proprietary drivers to obtain new indications or develop on-label superiority with a focus on hematology and oncology.
Our approach
Identify Blockbuster Candidates
- Screened universe of ~88k small molecules, 5 active ingredients prioritized for transdermal delivery*
- Opportunity for patient outcome improvement by addressing unmet need
- Technological fit with transdermal technology
- Freedom to operate and path for IP protection
Reimagine Potential to Improve Outcomes
- Conduct disease model studies to target improvements
- Develop new dose regimens
- Define optimal target to deliver superior outcomes or obtain a new indication vs innovator
- Improve efficacy and/or reduce toxicities
Execute on Strategy
- Built team with experience in preclinical and clinical development, and transdermal product development
- High caliber management team, advisory network, and Board of Directors
- Continue to attract top-tier collaborators and meet milestone
The company reformulates existing medicines that are well characterized and have a long and robust medical history. As result, Starton will be able to leverage the 505(b)2 regulatory path, enabling lower risk, a shortened development timeline, and significantly reduced financial investment.